Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Consensus Target Price from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received an average rating of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $23.40.

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research note on Friday, November 22nd.

Neumora Therapeutics Stock Up 0.6 %

Shares of NASDAQ:NMRA opened at $10.58 on Friday. The firm has a fifty day moving average of $12.18 and a two-hundred day moving average of $11.49. The firm has a market capitalization of $1.71 billion, a P/E ratio of -5.51 and a beta of 3.37. Neumora Therapeutics has a 12-month low of $8.33 and a 12-month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter in the prior year, the business earned ($1.14) EPS. Equities research analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the transaction, the director now owns 20,100 shares in the company, valued at approximately $342,303. The trade was a 41.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total transaction of $363,606.28. Following the transaction, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. The trade was a 8.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,400 shares of company stock worth $686,361 in the last quarter. 26.40% of the stock is currently owned by company insiders.

Institutional Trading of Neumora Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after acquiring an additional 694,385 shares during the period. State Street Corp increased its stake in Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after acquiring an additional 707,409 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Neumora Therapeutics by 139.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after acquiring an additional 406,891 shares during the period. Callan Capital LLC increased its stake in Neumora Therapeutics by 222.6% in the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after acquiring an additional 456,207 shares during the period. Finally, Auour Investments LLC bought a new stake in Neumora Therapeutics in the third quarter valued at about $3,302,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.